Compare MBIN & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBIN | ANAB |
|---|---|---|
| Founded | 1990 | 2005 |
| Country | United States | United States |
| Employees | 663 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2017 | 2017 |
| Metric | MBIN | ANAB |
|---|---|---|
| Price | $34.94 | $47.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $39.67 | ★ $60.18 |
| AVG Volume (30 Days) | 136.2K | ★ 499.2K |
| Earning Date | 01-28-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.34 | N/A |
| Revenue | ★ $597,247,000.00 | $169,467,000.00 |
| Revenue This Year | $5.17 | $135.51 |
| Revenue Next Year | $7.24 | N/A |
| P/E Ratio | $8.13 | ★ N/A |
| Revenue Growth | N/A | ★ 196.42 |
| 52 Week Low | $27.25 | $12.21 |
| 52 Week High | $43.82 | $52.47 |
| Indicator | MBIN | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 53.20 |
| Support Level | $34.51 | $46.06 |
| Resistance Level | $36.82 | $50.00 |
| Average True Range (ATR) | 0.97 | 3.02 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 28.77 | 64.38 |
Merchants Bancorp is a United States based bank holding company. It operates multiple lines of business focusing on FHA (Federal Housing Administration) multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. The business segments of the company are: Multi-family Mortgage Banking which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing segment which funds agency-eligible residential loans as well as commercial loans to nondepository financial institutions; and the Banking segment, which generates maximum revenue, and provides various financial products and services to consumers and businesses.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).